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Abstract
Background: PERK eIF2a kinase is required for the proliferation of the insulin-secreting beta- cells as well as insulin synthesis
and secretion. In addition, PERK signaling has been found to be an important factor in determining growth and
angiogenesis of specific types of tumors, and was attributed to PERK-dependent regulation of the hypoxic stress response.
In this report we examine the role of PERK in regulating proliferation and angiogenesis of transformed beta-cells in the
development of insulinomas.
Methodology: The SV40 Large T-antigen (Tag) was genetically introduced into the insulin secreting beta-cells of Perk KO
mice under the control of an inducible promoter. Tumor growth and the related parameters of cell proliferation were
measured. In late stage insulinomas the degree of vascularity was determined.
Principal Findings: The formation and growth of insulinomas in Perk-deficient mice was dramatically ablated with much
fewer tumors, which averaged 38-fold smaller than seen in wild-type control mice. Beta-cell proliferation was ablated in
Perk-deficient mice associated with reduced tumor growth. In the small number of large encapsulated insulinomas that
developed in Perk-deficient mice, we found a dramatic reduction in tumor vascularity compared to similar sized insulinomas
in wild-type mice. Although insulinoma growth in Perk-deficient mice was largely impaired, beta-cell mass was increased
sufficiently by T-antigen induction to rescue the hypoinsulinemia and diabetes in these mice.
Conclusions: We conclude that PERK has two roles in the development of beta-cell insulinomas, first to support rapid cell
proliferation during the initial transition to islet hyperplasia and later to promote angiogenesis during the progression to
late-stage encapsulated tumors.
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Introduction
Tumor growth is dependent upon high rates of protein
synthesis, and previous studies had shown that control of protein
synthesis mediated by phosphorylation of the translation initiation
factor eIF2a is important for tumor progression [1,2,3,4]. Humans
and other mammals have four eIF2a kinases including GCN2,
HRI, PKR and PERK. Previous studies have shown that tumors
that lack PERK-mediated signaling tend to be smaller and this was
found to be correlated with smaller hypoxic microenvironments
[5,6,7]. In these studies immortalized Perk-deficient MEFs
transformed with oncogenic Ki-RasV12 or HT29 colorectal
carcinoma cells stably expressing a dominant negative Perk allele
[8] were transplanted into nude mice [6,7]. The resultant tumors
were found to be smaller and less vascular compared to control
implants that were wild type for Perk [6,7]. However, in these
studies, the dramatic reduction in growth of the Perk-deficient
tumors was attributed to increased rates of apoptotic cell death
and impaired angiogenesis but, inexplicably, tumor cell prolifer-
ation rates were not examined [6,7].
Perk deficiency in humans is the cause of the Wolcott-Rallison
Syndrome characterized by permanent neonatal diabetes, exo-
crine pancreas deficiency, osteopenia, and growth retardation [9]
and these defects are recapitulated in Perk KO mice [10,11,12].
We discovered that the diabetes in Perk KO mice was due to
hypoinsulinemia associated with low insulin-secreting beta-cell
mass caused by diminished beta-cell proliferation and impaired
insulin secretion [13]. Gene expression analyses revealed reduced
expression of factors vital to the G2-M cell cycle transition [13].
Moreover, Perk-deficient osteoblasts exhibited reduced levels of cell
proliferation [14]. Having established the importance of PERK in
beta-cell proliferation we decided to investigate whether PERK
played an important role in the progression of insulinomas, a
pancreatic beta-cell cancer.
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Growth of Insulinomas Induced by the SV40 Large T-
Antigen Is Severely Blunted in PERK-Deficient Mice
To generate insulinomas in mice, the SV40 Large T-Antigen
was introduced using a bipartite genetic system comprised of the
tet-Tag transgene and the RIP7-rtTA transgene. Together these
transgenes (denoted bTag) provide beta-cell specific, doxycycline-
inducible control of the expression of the T-antigen [15]. These
strains were further crossed into Perk KO (PKO) mice to study the
effect of Perk on postnatal b-cell proliferation. As reported
previously, we found that the expression of bTag in wild-type
(WT-bTag) mice caused islet hyperplasia by postnatal day 40 (p40)
(Figure 1A–B), and these hyperplastic islets progressed to highly
vascular insulinomas associated with hyperinsulinemia and
hypoglycemia (arrows, Figure 1C) [15]. Serum insulin increased
by .40-fold compared to normal in some animals (not shown).
In the absence of bTag, Perk-deficient mice have a low beta-cell
massat postnatal day p14(Figure 1D) and progress to overt diabetes
by p21 [13]. Most Perk KO mice die due to numerous complications
by 5 to 6 weeks of life [12]. Introduction of bTag into Perk KO mice
(PKO-bTag) resulted in partial rescue of the beta-cell mass in p40
juvenile mice (Figure 1E) and delayed the onset of overt diabetes by
one week. Remarkably, continued islet growth and increased beta-
cell massresulted incompletereversalofthediabetesby7–10 weeks
(Figure 2). Blood glucose levels in PKO-bTag mice were found to
peak by p35-p40, followed by a gradual progression to hypoglyce-
mia (Figure 2). Although T-antigen expression was able to induce
beta-cellproliferation andreverse diabetes inthe Perk KOmouse,the
size of their insulinomas were on average 38-fold smaller than seen
in wild-type littermates (Figure 3).
Beta-Cell Death Does Not Explain the Reduced Beta-Cell
Mass in PKO-bTag Mice
To determine if differential cell death may be the cause for the
relatively small size of the insulinoma in PKO-bTag mice, we
measured the percentage of beta-cells exhibiting TUNEL positive
nuclei in PKO-bTag and WT-bTag mice during the exponential
growth phase of the developing beta-cell tumors. Examination of
islets smaller or larger than 1,000 beta-cells revealed that the
percentage of TUNEL positive beta-cells was modestly higher in
WT-bTag mice compared to PKO-bTag mice for both islet size
classes (Figure 4A–C) but did not reach statistical significance. In
one WT-bTag mouse we examined an extraordinarily large tumor
and found dense clusters of TUNEL positive beta-cells (Figure 4D).
Within the local region of these clusters .10% of the beta-cells
were TUNEL positive whereas the majority of the tumor exhibited
a frequency of less than 1% similar to the other tumors in WT-
bTag mice. The data from this exceptional tumor were not
included in Figure 4C. Although beta-cell death may contribute to
the tumor size difference between WT-bTag mice and PKO-bTag
mice these data suggest that cell death differences would tend to
lessen the difference between these genotypes.
Beta-Cell Proliferation in PKO-bTag Mice Is Reduced
Compared to WT-bTag Mice
The rates of beta-cell proliferation in PKO-bTag mice and age
and sex matched WT-bTag littermates were estimated by BrdU
Figure 1. The growth of beta-cell insulinomas is ablated in
Perk-deficient mice. (A–B) Pancreata of wildtype (WT) mice with (A)
or without (B) beta-cell specific SV40 T-antigen (bTag) were examined
histologically after hematoxlin and eosin staining to assess relative
beta-cell hyperplasia at postnatal day 40 (p40). (C) Representative
necropsy image of the whole pancreata of a p120 WT-bTag mouse
showing multiple insulinomas dispersed throughout the pancreas
(arrows). (D) Perk KO (PKO) mice displayed relatively small islets at p14.
(E) PKO-bTag mice exhibited increased beta cell mass.
doi:10.1371/journal.pone.0008008.g001
Figure 2. Beta-cell hyperplasia caused by T-antigen transfor-
mation reverses diabetes in Perk KO mice. Serum glucose levels
(mg/dl) in wildtype (WT, closed squares and solid line), wildtype-bTag
(WT-bTag, open squares and dashed line), Perk KO (PKO, closed triangles
and solid line) and Perk KO-bTag (PKO-bTag, open triangles and dashed
line) littermates during postnatal progression of insulinoma develop-
ment. Each data point is the mean of 4 to 13 mice. Serum glucose in
PKO mice often exceeded the detection capability of the blood glucose
monitor (600 mg/dl) and these mice didn’t survive beyond p45. In this
figure and all others, error bars=SEM.
doi:10.1371/journal.pone.0008008.g002
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proliferation, beta-cell proliferation rates were assessed in uniform
islets of less than 50 cells in PKO-bTag and their WT-bTag
littermates at the following postnatal ages: p50, p100, and p120.
PKO-bTag islets showed a statistically significant 2.2 fold reduction
in beta-cell proliferation (Table 1). Furthermore, rates of beta-cell
proliferation were found to be consistently reduced in PKO-bTag
mice both in the early phases of bTag induced islet hyperplasia at
p50 (3.1 fold difference) as well as in the later stages of the
progression to insulinomas at p120 (1.6 fold difference) (Table 1).
Although the expression of the T-antigen in beta-cells leads to a
dramatic increase in beta-cell proliferation in adult mice, we found
that beta-cell masses at embryonic day 16.5 were not significantly
different either between wild-type mice with or without bTag
expression as well as their PKO-bTag littermates (not shown). Our
findings that bTag expression did not significantly affect beta-cell
mass in wild-type and Perk-deficient mice in embryonic mice (e16.5)
is consistent with previous reports that have shown that bTag
promotes postnatal beta-cell proliferation beginning at about 3
weeks [15]. Furthermore, Tag is an oncogene that functions
primarily by inactivating the retinoblastoma protein (the main gate-
keeper for the G1-S cell cycle checkpoint) and p53 (an inducer of
apoptosis) [15], and previous studies have shown that the negative
regulation of the G1-S cell cycle checkpoint does not significantly
affect late-embryonic beta-cell neogenesis [16]. Our lab has also
shown that beta-cell mass in Perk-deficient mice is comparable to
their wild-type littermates in the early embryonic stages following
neogenesis of beta-cells from endocrine progenitor cells [13].
T-Antigen Induced Insulinoma Vascularity Is Greatly
Diminished in Perk-Deficient Mice
T-antigen induced beta-cell proliferation eventually leads to the
formation of insulinomas [15,17]. These insulinomas exhibited a
marked increase in vascularity by 11–14 weeks (Figure 1E)
compared to the initial stages of islet hyperplasia (4–6 weeks).
Histological examination of WT-bTag insulinomas at p120
revealed highly vascularized tumors (Fig. 5A, C, E). In contrast,
insulinomas from PKO-bTag littermates appeared to have
significantly reduced tumor vascularity (Figure 5B). Because
PKO-bTag tumors are generally much smaller, their lack of
vascularity could be simply due to a failure to progress to late stage
insulinoma. To address this issue, we compared size-matched
insulinomas from Perk KO and wild-type mice, and found a
statistically significant 3-fold decrease in tumor vascularity in PKO-
bTag insulinomas (Figure 5G). Moreover, in the small number of
very large encapsulated insulinomas in PKO-bTag mice, we found
a dramatic reduction in tumor vascularity (Figure 5D) compared
to size-matched tumors in WT-bTag mice (Figure 5C).
Discussion
Previous studies have identified three distinct stages of T-antigen-
induced beta-cell tumor progression including islet hyperplasia,
islet-angiogenesis and finally formation of solid encapsulated tumors
[18,19].Thepredominantdeterminant inthe progression ofnormal
islets to a stage of hyperplasia and angiogenesis was found to be the
rate of beta-cell proliferation, while reduced apoptosis was critical in
the progression to solid encapsulated tumors [18,19]. As expected,
we observed a similar progression to insulinomas and associated
hyperinsulinemia-hypoglycemia in wildtype-bTag mice. However,
beta-cell proliferation was significantly reduced in Perk-deficient
bTag mice and this defect was most prominent in the initial
transition to islet hyperplasia. Insulinomas in Perk KO-bTag mice
were fewer, the average size was 38-fold smaller, and they rarely
develop into encapsulated tumors. Cell death was slightly higher in
wildtype-bTag mice and therefore does not appear to contribute to
the smaller size of tumors in Perk KO-bTag mice. Beta-cells isolated
from Perk KO-bTag insulinomas also showed poor growth
characteristics in culture, and we were unable to establish a T-
antigen, Perk-deficient beta-cell line from isolated insulinomas from
these mice whereas we could readily establish them from the
wildtype-bTag mice. Although the T-antigen induction of beta-cell
proliferation in Perk KO was blunted compared to the wild-type
mice, the increase in beta-cell mass was nonetheless sufficient to
eventually reverse the diabetes of these mice.
During the later stages of tumor development hypoxia becomes
more prevalent as cell growth outstrips the pre-existing vascular
system [5,20]. To provide increased circulation within the tumor
microenvironment, angiogenesis is induced in part by the response
to hypoxia [21]. PERK has been shown to be important for
regulating the hypoxic stress response in fibroblast-derived tumors
[6,7] and it was speculated that the slow growth of Perk-deficient
tumors was caused by a defect in the hypoxia-stress response
resulting in increased cell death. We found that Perk-deficient
insulinomas failed to develop extensive vasculature, consistent with
the hypothesis that PERK plays a critical role in regulating the
response to hypoxia. However, we discovered that beta-cell
proliferation and beta-cell mass in Perk KO-bTag islets substantially
lagged behind wildtype-bTag islets during the initial hyperplasia
stage prior to the time that hypoxic conditions exist. Moreover,
beta-cell death was actually slightly higher in the islets of the
wildtype-bTag mice during the exponential growth phase and
therefore does not contribute to the relatively small size of the Perk
Figure 3. Relative tumor volumes in bTag induced insulinomas
in wild type and Perk KO littermates. The insulinomas exhibited a
nearly spherical shape and therefore tumor volumes were estimated as
a function of their diameter. The tumor volumes of the largest
insulinomas from three PKO-bTag mice (n=23) and 6 WT-bTag mice
(n=19) at age p120 are plotted on a logarithmic scale showing a 38-
fold difference. *****P,0.000005.
doi:10.1371/journal.pone.0008008.g003
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formation, first to support rapid cell proliferation and then later to
promote angiogenesis. In the absence of PERK, however, tumors
may not achieve sufficient size in order for severe hypoxia and cell
death to occur. We found high apparent beta-cell death only in a
very large wildtype-bTag insulinoma, but similarly sized insulinomas
Figure 4. Beta-cell death does not significantly contribute to tumor size differences between Perk genotypes. TUNEL positive beta-cells
were detected by immunohistochemistry. (TUNEL=red, insulin=green). (A) WT-bTag islet p120, 40X, (B) PKO-bTag islet p120, 40X, (C) Beta-cell death
was estimated as the percentage of beta-cells (insulin positive) that exhibited a high level of DNA fragmentation as detected by TUNEL antibody in
the nucleus. Islets were categorized into two groups: smaller than 1,000 beta-cells and larger than 1,000 beta-cells counted on a single cross-sectional
area of each islet. The mean and standard error are shown for TUNEL positive beta-cells for each islet size class. No significant differences were seen
between genotypes for either size class. For the small islet size class, WT-bTag n=27 islets (12,946 total beta-cells) and PKO-bTag n=20 islets (4,749
total beta-cells). For the large islet size class, WT-bTag mice n=20 islets (138,858 total beta-cells) and PKO-bTag n=12 islets (59,109 total beta-cells).
(D) A small section of a very large beta-cell insulinoma from a p120 WT-bTag mouse showing a high density of TUNEL positive beta-cells (40X). Four
other distinct clusters of beta-cells also showed very high percentage of beta-cells that were TUNEL positive in this cross section of the tumor (not
shown), whereas the majority of tumor exhibited a frequency of less than 1% TUNEL positive beta-cells. The TUNEL positive beta-cell clusters tend to
be centrally located in the tumor.
doi:10.1371/journal.pone.0008008.g004
Table 1. Beta-cell proliferation is impaired in Perk-deficient, T-antigen transformed islets.
Genotype Postnatal Age Analysis Criteria Beta-cells/islet % BrdU+ cells
WT-bTag p50, n=1 all islets, n=7 204.7 5.6
PKO-bTag p50, n=1 all islets, n=8 40.3 1.8
P,0.05
WT-bTag p50/100/120, n=3 islets,50 cells, n=28 39.6 4.6
PKO-bTag p50/100/120, n=3 islets,50 cells, n=25 21.6 2.1
P,0.05
WT-bTag p120, n=1 islets.500 cells, n=9 3869.2 8.0
PKO-bTag p120, n=1 islets.500 cells, n=11 2115.2 5.1
P,0.05
Beta-cell proliferation rates were assessed by BrdU incorporation in age and sex matched PKO-bTag mice and WT-bTag littermates at postnatal ages p50, p100 and p120.
Cells=insulin-positive beta-cells.
doi:10.1371/journal.pone.0008008.t001
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in late stage tumor progression it will be necessary to acutely ablate
PERK expression later in tumor development.
In addition to regulating beta-cell functions that contribute
tumor progression, PERK may also regulate functions in other cell
types including the vascular endothelial cells that comprise the
tumor macroenvironment. In our studies Perk is deficient in all cells
of the entire animal, and therefore we cannot discriminate
between PERK’s functions in these different cell types. We are
currently generating Tag-induced insulinomas in mice in which
Perk has been specifically ablated in various cell types of the
pancreas to determine the role of PERK in both the beta-cells and
macroenvironment of the developing tumor.
The molecular mechanism underlying PERK-dependent regu-
lation of tumor growth and angiogenesis is unknown. We speculate
that reduced proliferation and vascularity in Perk-deficient
insulinomas is caused by a fundamental defect in function in the
secretory pathway that we have recently discovered in beta-cells.
Perk-deficient beta-cells have defects in [13] ER to Golgi
trafficking, ER associated proteasomal degradation, and integrity
of the ER and Golgi (unpublished). Cell proliferation and
membrane targeting of angiogenic receptors (e.g. VEGFRs) are
highly dependent upon normal ER functions. We therefore
suggest that these defects in ER functions may negatively impact
beta-cell proliferation and angiogenesis.
Ethics
All the procedures that involved animal subjects were approved
by the IACUC of the Pennsylvania State University in accordance
withfederalandstate regulations governingcare anduseof animals.
Figure 5. Perk-deficient insulinomas exhibit dramatically reduced vascularity. (A–D): Insulinomas from p120 WT-bTag (A, C) and PKO-bTag
(B, D) mice stained with hematoxylin and eosin. Insulinomas from p120 WT-bTag (E) and PKO-bTag (F) littermates were stained for insulin (green),
BrdU (red) and DAPI (blue). (E) Note the red autofluorescent signal from red blood cells within the highly vascularized WT-bTag insulinomas. (G) The
vascularized area in the cross sectional images of the islets were expressed as a percentage of the total islet area in PKO-bTag mice and WT-bTag
littermates at p120. For each islet, the percentage vascularized area was plotted on the y-axis and the corresponding islet size was plotted on the x-
axis. WT-bTag: n=2 mice, number of islets analyzed=37, solid line represents the linear trend, average islet size=1367.2, and the percent
vascularized area=8.9%. PKO-bTag: n=2 mice, number of islets analyzed=30, dashed line represents the linear trend, average islet size=898.3, and
the percentage vascularized area=2.9%. The difference in the average value of the vascularized area between PKO-bTag and WT-bTag was highly
significant, ***P-value,0.0005.
doi:10.1371/journal.pone.0008008.g005
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Genetic Strains
Mice expressing SV40 large T-antigen conditionally in beta-
cells were generated by crossing heterozygous tet-Tag transgenic
mice with heterozygous RIP7-rtTA transgenic mice [15]. To
activate Tag expression, double-transgenic mice (denoted as bTag)
were treated with 2 mg/ml doxycycline (Sigma) (in 2.5% sucrose)
in their drinking water. Doxycycline treatment was administered
in utero and continued postnatally. Untreated double-transgenic
mice or doxycycline-treated mice lacking one of the two transgenes
served as controls. These mice were further crossed into Perk
+/2
strains [12] to generate PKO-bTag and WT-bTag mice. All the
strains were in a mixed genetic background. All the procedures
that involved animal subjects were approved by the IACUC of the
Pennsylvania State University.
Blood Glucose Measurements
Blood samples were obtained from the tail and were measured
for glucose concentration using the Accu-Chek or OneTouch
Ultra glucometers.
Histological Analyses and Immunohistochemistry
After the animals were sacrificed by CO2 asphyxiation, the
pancreata were removed, fixed in 4% paraformaldehyde,
dehydrated, paraffin-embedded and sectioned. Sections were
processed for immunohistochemistry or stained with hematoxylin
and eosin (H & E) by standard procedures. Briefly, cells were
permeabilized in 0.2% Triton-X in phosphate-buffered saline
(PBS) for 10 minutes. In the case of BrdU, antigen retrieval was
performed by boiling in citric buffer for 10 mins. This was
followed by serial incubations with the appropriate primary and
secondary antibodies. The following antibodies were used: insulin
(Linco Research), glucagon (Santa Cruz), proinsulin (Beta-Cell
Biology Consortium), and BrdU (DAKO). Appropriate secondary
antibodies conjugated with Alexa Fluor 488 or 555 dye (Molecular
Probes) were used to visualize the labels. DAPI was used for
nuclear staining. Fluorescence images were captured and analyzed
with a Nikon Eclipse E1000 microscope and Image-Pro Plus
Software (Phase 3 Imaging Systems).
Beta-Cell Mass and Proliferation Analysis
Mice were injected intraperitoneally with 100 mg BrdU/gram
body weight. The pancreata were removed 6 hrs later, and
processed. For the estimation of beta-cell mass, embryonic
pancreata were processed and all of the islets in a total of 6 tissue
sections (covering the entire pancreas) were analyzed.
Statistical Analysis
Statistical analysis was performed using Student’s t-test; P,0.05
was accepted as significant. Error bars represent the standard error
of mean (SEM).
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